2. Search Result
Search Result
Results for "

platelet-rich plasma,alopecia areata

" in MedChemExpress (MCE) Product Catalog:

57

Inhibitors & Agonists

1

Biochemical Assay Reagents

3

Peptides

3

Inhibitory Antibodies

8

Natural
Products

5

Isotope-Labeled Compounds

Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-100754
    Ritlecitinib
    Maximum Cited Publications
    8 Publications Verification

    PF-06651600

    		 JAK Interleukin Related STAT Inflammation/Immunology
    Ritlecitinib (PF-06651600) is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC50=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC50 >10 μ M). Ritlecitinib rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE) .
    Ritlecitinib
  • HY-P0074
    GPRP
    3 Publications Verification

    Gly-Pro-Arg-Pro; Pefa 6003

    		 Thrombin Cardiovascular Disease
    GPRP (Gly-Pro-Arg-Pro; Pefa 6003) is a fibrin polymerization inhibitor that inhibits the interaction between fibrinogen and the platelet membrane glycoprotein Ⅱb/IIIa complex (glycoprotein IIb/IIIa receptor) . GPRP increases the level of free thrombin in activated platelet-rich plasma by reducing the adsorption of thrombin onto fibrin. GPRP inhibits platelet aggregation and prolongs the thrombin-initiated clotting time in plasma. GPRP is applicable for research related to thrombosis and thrombotic diseases .
    GPRP
  • HY-50856S
    Deuruxolitinib

    CTP-543; Ruxolitinib d8; Deuterated Ruxolitinib

    		 JAK Inflammation/Immunology
    Deuruxolitinib, a deuterated Ruxolitinib (HY-50856), is an orally active JAK1 and JAK2 inhibitor. Deuruxolitinib demonstrates significant hair regrowth effects. Deuruxolitinib can be used for the research of alopecia areata .
    Deuruxolitinib
  • HY-B1064
    Clindamycin phosphate
    4 Publications Verification

    Clindamycin 2-phosphate; U-28508

    		 Bacterial Antibiotic Parasite Infection Cancer
    Clindamycin phosphate (Clindamycin 2-phosphate) is a broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin phosphate is the proagent of Clindamycin (HY-B1455) with no antimicrobial activity in vitro but can be rapidly converted in vivo to the active parent agent, Clindamycin, by phosphatase ester hydrolysis. Clindamycin phosphate can be used for researching acne and bacterial vaginosis . Clindamycin phosphate has no cytotoxicity. Combined with platelet rich fibrin (PRF), PRF-Clindamycin phosphate enhances antimicrobial properties .
    Clindamycin phosphate
  • HY-100754C
    Ritlecitinib tosylate
    Maximum Cited Publications
    8 Publications Verification

    PF-06651600 tosylate

    		 JAK Interleukin Related STAT Inflammation/Immunology
    Ritlecitinib (PF-06651600) tosylate is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC50=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC50 >10 μ M). Ritlecitinib tosylate rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib tosylate can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE) .
    Ritlecitinib tosylate
  • HY-N1775
    3',4'-Dihydroxyacetophenone

    3,4-DHAP

    		 Tyrosinase Reactive Oxygen Species (ROS) Keap1-Nrf2 PARP Autophagy Apoptosis Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    3',4'-Dihydroxyacetophenone (3,4-DHAP) is a phenolic compound with oral bioavailability, possessing potent antioxidant, anti-inflammatory, anticancer and cardiovascular protective activities. 3',4'-Dihydroxyacetophenone inhibits mushroom Tyrosinase activity with an IC50 of 10 μM, thereby suppressing melanogenesis . 3',4'-Dihydroxyacetophenone inhibits platelet aggregation in platelet-rich plasma. 3',4'-Dihydroxyacetophenone reduces ROS levels in human umbilical vein endothelial cells treated with high glucose, upregulates the expression of Nrf2, HO-1 and PARP-1 in cells, and promotes the nuclear translocation of Nrf2 . 3',4'-Dihydroxyacetophenone induces autophagy and apoptosis. 3',4'-Dihydroxyacetophenone inhibits seed germination/growth in most plants. 3',4'-Dihydroxyacetophenone can be used in the research of cancer, neurodegenerative diseases, non-alcoholic steatohepatitis, diabetes, obesity, skin pigmentation disorders, and cardiovascular and cerebrovascular diseases .
    3',4'-Dihydroxyacetophenone
  • HY-B0426A
    Olopatadine hydrochloride

    ALO4943A; KW4679

    		 Histamine Receptor CXCR Infection Neurological Disease Metabolic Disease Inflammation/Immunology
    Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 + and CD8 + T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .
    Olopatadine hydrochloride
  • HY-P990023
    Bempikibart

    ADX-914

    		 Interleukin Related Metabolic Disease Inflammation/Immunology
    Bempikibart (ADX-914) is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking signaling mediated by both IL-7 and thymic stromal lymphopoietin (TSLP). Bempikibart can be used for the study of atopic dermatitis and alopecia areata .
    Bempikibart
  • HY-W014605
    Diphenylcyclopropenone

    Diphencyprone

    		 Interleukin Related Apoptosis p38 MAPK IRE1 Inflammation/Immunology Cancer
    Diphenylcyclopropenone (Diphencyprone) is a potent hapten acting as a topical immunomodulatory agent, which induces an allergic contact dermatitis. Diphenylcyclopropenone induces an increase of cell-surface thiols in cells of a human monocytic cell line, THP-1. Diphenylcyclopropenone acts on the autoreactive T-lymphocytes within the follicular milieu to induce Apoptosis. Diphenylcyclopropenone can be used for alopecia areata research .
    Diphenylcyclopropenone
  • HY-P5253
    Octapeptide-2

    		Apoptosis Metabolic Disease
    Octapeptide-2 is a biomimetic peptide that mimics the thymosin-β4 growth factor. Octapeptide-2 can promote hair growth, reduce cell apoptosis, and increase the proliferation of keratinocytes. Octapeptide-2 can be used in the research of hair loss and alopecia areata .
    Octapeptide-2
  • HY-128039
    17-Phenyl-ω-trinor-PGE2

    		Prostaglandin Receptor Others
    17-Phenyl-ω-trinor-PGE2 is a PGE2 (HY-101952) analog, which is an agonist for EP1 and EP3 receptor. 17-Phenyl-ω-trinor-PGE2 inhibits the PAF-induced aggregation of human platelet-rich plasma (PRP) and Cicaprost (HY-19583) induced Cyclic AMP (HY-B1511) production .
    17-Phenyl-ω-trinor-PGE2
  • HY-W062109
    Olopatadine

    		Histamine Receptor CXCR Inflammation/Immunology
    Olopatadine (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine also reduces the expression levels of CXCR3 on the surface of CD4 + and CD8 + T cells. Olopatadine inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .
    Olopatadine
  • HY-P5232
    Tetrapeptide-21

    		Collagen Metabolic Disease
    Tetrapeptide-21 is a bioactive peptide composed of four amino acids. Tetrapeptide-21 effectively enhances the vitality of human dermal fibroblasts. Tetrapeptide-21 upregulates the expression of key extracellular matrix (ECM) genes and promotes the synthesis of ECM proteins (such as type I collagen, hyaluronic acid synthase 1, and fibronectin). Tetrapeptide-21 has the efficacy of anti-wrinkle and improving skin elasticity, and has been reported to be used as a cosmetic ingredient .
    Tetrapeptide-21
  • HY-N3228
    Myrianthic acid

    		Others Cardiovascular Disease
    Myrianthic acid is a pentacyclic triterpenoid compound. Myrianthic acid can exist in the root wood of Myrianthus arboreus and the leaves of Campsis grandiflora. Myrianthic acid inhibits adrenaline-induced platelet aggregation, with a IC50 of 46.2 μM for this activity. Myrianthic acid can be used in studies related to thrombosis .
    Myrianthic acid
  • HY-P990209
    Anti-Mouse IL-7Rα/CD127 Antibody (A7R34)
    1 Publications Verification

    		 Interleukin Related Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Anti-Mouse IL-7Rα/CD127 Antibody (A7R34) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse IL-7Rα/CD127. Anti-Mouse IL-7Rα/CD127 Antibody (A7R34) blocks IL-7 signaling. Anti-Mouse IL-7Rα/CD127 Antibody (A7R34) can be used for the researches of cancer,infection, inflammation, immunology, cardiovascular and metabolic disease, such as abdominal aortic aneurysms, helicobacter felis-induced gastritis and diabetes .
    Anti-Mouse IL-7Rα/CD127 Antibody (A7R34)
  • HY-123669
    R-138727

    		P2Y Receptor Drug Metabolite Cardiovascular Disease
    R-138727, the major active metabolite of Prasugrel (HY-15284), is a highly potent and selective irreversible antagonist of the P2Y12 receptor, with an IC50 of 2.5 μM. R-138727 covalently binds to the P2Y12 receptor on the platelet surface, blocking adenosine diphosphate-mediated platelet activation and aggregation. R-138727 can be used to study stroke, cerebral infarction and neurological deficits.
    R-138727
  • HY-B2198
    Carpronium chloride

    Actinomin chloride

    		 Cholinesterase (ChE) Neurological Disease
    Carpronium (Actinomin) chloride is an orally active cholinergic agonist, local vasodilator and parasympathomimetic agent. Carpronium chloride is structurally similar to acetylcholine. Carpronium chloride promotes hair growth, and oral overdose induces cholinergic crisis. Carpronium chloride is applicable to research related to alopecia areata .
    Carpronium chloride
  • HY-172374
    KV1.3-IN-2

    		Potassium Channel Inflammation/Immunology
    KV1.3-IN-2 is a kv1.3 potassium channel inhibitor without affecting hERG channel activity. KV1.3-IN-2 can be used in research of immune-related diseases such as psoriasis, rheumatoid arthritis, and systemic lupus erythematosus .
    KV1.3-IN-2
  • HY-135447
    BM-531

    		Prostaglandin Receptor Others
    BM-531 is a dual-acting agent for thromboxane receptor (TXA2) antagonism and thromboxane synthase inhibition. BM-531 exerts anti-aggregatory effects on human citrated platelet-rich plasma (PRP), inhibiting Arachidonic acid (HY-109590A)-induced aggregation with an ED100 of 0.125 μM and U-46619 (HY-108566)-induced aggregation with an ED50 of 0.482 μM. BM-531 inhibits high-K +-induced contraction of porcine uterine smooth muscle .
    BM-531
  • HY-Y1094
    [Rh(cod)Cl]2

    Chloro(1,5-cyclooctadiene)rhodium(I) dimer

    		 Biochemical Assay Reagents Cardiovascular Disease
    [Rh(cod)Cl]2 (Chloro(1,5-cyclooctadiene)rhodium(I) dimer) is a rhodium (I) organometallic dimer complex. [Rh(cod)Cl]2 can inhibit platelet-activating factor-mediated platelet aggregation with IC50 values of 5.2 and 43.3 μM in washed rabbit platelets and human platelet-rich plasmas. [Rh(cod)Cl]2 also can inhibit thrombin-, ADP (HY-W010918)- and collagen-induced aggregation with IC50 values of 16.7, 162 and 69.8 μM. [Rh(cod)Cl]2 can be used for the research of cardiovascular disease, such as thrombosis .
    [Rh(cod)Cl]2
  • HY-137584
    1a,1b-Dihomo prostaglandin E1

    1a,1b-Dihomo PGE1

    		 Prostaglandin Receptor Cardiovascular Disease
    1a,1b-Dihomo prostaglandin E1 (1a,1b-Dihomo PGE1) is an E1-type prostaglandin. 1a,1b-Dihomo prostaglandin E1 can be used for research on platelet aggregation .
    1a,1b-Dihomo prostaglandin E1
  • HY-W062109S
    Olopatadine-d6

    		Isotope-Labeled Compounds Histamine Receptor CXCR Inflammation/Immunology
    Olopatadine-d6 is the deuterium labeled Olopatadine. Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 + and CD8 + T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .
    Olopatadine-d6
  • HY-163341
    PAR4 antagonist 1

    		Protease Activated Receptor (PAR) Cardiovascular Disease
    PAR4 antagonist 1 (Compound 48) is a protease activated receptor 4 (PAR4) antagonist with an IC50 of 1.8 nM. PAR4 antagonist 1 has an IC50 of 2 nM against γ-thrombin-activated PAR4 in platelet-rich plasma (PRP). PAR4 antagonist 1 can be used in antithrombotic research .
    PAR4 antagonist 1
  • HY-128345
    UDM-001651

    		Protease Activated Receptor (PAR) Cardiovascular Disease
    UDM-001651 is a potent, selective, and orally bioavailable protease-activated receptor 4 (PAR4) antagonist (IC50=4 nM; Kd=1.4 nM). UDM-001651 shows antiplatelet potency (IC50=25 nM) in a γ-thrombin-induced platelet-rich plasma aggregation assay (γ-Thr PRP) .
    UDM-001651
  • HY-100754A
    Ritlecitinib malonate

    PF-06651600 malonate

    		 JAK Interleukin Related STAT Inflammation/Immunology
    Ritlecitinib (PF-06651600) malonate is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC50=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC50 >10 μ M). Ritlecitinib malonate rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib malonate can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE) .
    Ritlecitinib malonate
  • HY-B0426AS
    Olopatadine-d3 hydrochloride

    		Isotope-Labeled Compounds Histamine Receptor CXCR Inflammation/Immunology Endocrinology
    Olopatadine-d3 hydrochloride (ALO4943A-d3) is the deuterium labeled Olopatadine hydrochloride. Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 + and CD8 + T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .
    Olopatadine-d3 hydrochloride
  • HY-B0426AR
    Olopatadine hydrochloride (Standard)

    ALO4943A (Standard); KW4679 (Standard)

    		 Reference Standards Histamine Receptor CXCR Inflammation/Immunology Endocrinology
    Olopatadine (hydrochloride) (Standard) is the analytical standard of Olopatadine (hydrochloride). This product is intended for research and analytical applications. Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 + and CD8 + T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .
    Olopatadine hydrochloride (Standard)
  • HY-19755
    S-5751

    		Prostaglandin Receptor Inflammation/Immunology
    S-5751 is an orally active prostaglandin DP receptor antagonist. S-5751 inhibits cAMP generation in platelet-rich plasma induced by PGD2 with IC50 0.12 μM. S-5751 has anti-inflammatory activity. S-5751 can be used in asthma research .
    S-5751
  • HY-137591
    13,14-Dihydro-15-keto-PGE1

    		Drug Metabolite Endocrinology
    13,14-Dihydro-15-keto-PGE1 is an inactive metabolite of PGE1. 13, 14-Dihydro-15-Keto-pGE1 inhibited platelet aggregation in ADP-induced human isolated platelet-rich plasma with IC50 14.8 μg/mL .
    13,14-Dihydro-15-keto-PGE1
  • HY-19126
    CL-184005

    		Platelet-activating Factor Receptor (PAFR) Infection Cardiovascular Disease
    CL-184005 is an antagonist for platelet-activating factor (PAF), that inhibits the PAF-induced platelet aggregation with IC50 of 600 nM and 510 nM, in human and rabbit platelet-rich plasma. CL-184005 protects the rats from endotoxin-induced gastrointestinal damage and hypotension. CL-184005 exhibits potential attenuating Gram-negative bacterial sepsis .
    CL-184005
  • HY-176527
    (Rac)-TUL01101

    		JAK Inflammation/Immunology
    (Rac)-TUL01101 (Compound I) is a selective JAK kinase inhibitor. (Rac)-TUL01101 can be used in the research of various diseases such as rheumatoid arthritis, atopic dermatitis, and alopecia areata .
    (Rac)-TUL01101
  • HY-107000
    RIG 200

    		Guanylate Cyclase NO Synthase Cardiovascular Disease
    RIG 200 is an S-nitrosothiol nitric oxide (NO) donor. RIG 200 releases NO through decomposition, activating guanylate cyclase (sGCM) in vascular smooth muscle cells, increasing cGMP levels, and leading to vasodilation. RIG 200 significantly inhibits Collagen (HY-NP003)-induced platelet aggregation in platelet-rich plasma (PRP). RIG 200 may be used in research on antithrombus .
    RIG 200
  • HY-113113
    13,14-Dihydro PGE1

    13,14-Dihydroprostaglandin E1

    		 Endogenous Metabolite Metabolic Disease
    13,14-Dihydro PGE1 is a metabolite of PGE1 (Prostaglandin E1) which inhibits the ADP-induced platelet aggregation (ID50 = 10.8 ng/mL platelet rich plasma) .
    13,14-Dihydro PGE1
  • HY-108561
    L-670596

    		Prostaglandin Receptor Others
    L-670596 is an orally active and selective thrombsxane A2 receptor/prostaglandin receptor antagonist. L-670596 inhibits arachidonic acid (HY-109590) and U-44069 induced bronchoconstriction in the guinea pig. L-670596 also inhibits the aggregation of human platelet rich plasma induced by U-44069 .
    L-670596
  • HY-136068R
    DCAP (Standard)

    VU0607402 (Standard)

    		 Reference Standards Antibiotic Bacterial Autophagy Infection Cancer
    Diphenylcyclopropenone (Standard) is the analytical standard of Diphenylcyclopropenone. This product is intended for research and analytical applications. Diphenylcyclopropenone (Diphencyprone) is a topical immunomodulatory agent that can be used for alopecia areata research .
    DCAP (Standard)
  • HY-W014605R
    Diphenylcyclopropenone (Standard)

    Diphencyprone (Standard)

    		 Apoptosis IRE1 p38 MAPK Interleukin Related Reference Standards Inflammation/Immunology Cancer
    Diphenylcyclopropenone (Standard) is the analytical standard of Diphenylcyclopropenone. This product is intended for research and analytical applications. Diphenylcyclopropenone (Diphencyprone) is a topical immunomodulatory agent that can be used for alopecia areata research .
    Diphenylcyclopropenone (Standard)
  • HY-113113S
    13,14-Dihydro PGE1-d4

    13,14-Dihydroprostaglandin E1-d4; PGE0-d4

    		 Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    13,14-Dihydro PGE1-d4 (13,14-Dihydroprostaglandin E1-d4) is deuterium labeled 13,14-Dihydro PGE1. 13,14-Dihydro PGE1 is a metabolite of PGE1 (Prostaglandin E1) which inhibits the ADP-induced platelet aggregation (ID50 = 10.8 ng/mL platelet rich plasma) .
    13,14-Dihydro PGE1-d4
  • HY-137288
    17-Phenyl-18,19,20-trinor-PGD2

    17-Phenyl-PGD2

    		 Prostaglandin Receptor Cardiovascular Disease
    17-Phenyl-18,19,20-trinor-PGD2 (17-Phenyl-PGD2) is an analogue of prostaglandin D2 (PGD2; HY-101988). 17-Phenyl-18,19,20-trinor-PGD2 is a potent inhibitor of platelet aggregation caused by aenosine diphosphate (ADP), with the IC50 of 8.4 μM (PGD2 IC50 = 18.6 nM). 17-Phenyl-18,19,20-trinor-PGD2 is a weak agonist of cyclic AMP accumulation .
    17-Phenyl-18,19,20-trinor-PGD2
  • HY-172148
    Itaconic acid prodrug-1

    		Interleukin Related Inflammation/Immunology
    Itaconic acid prodrug-1 (Compound P2) is an orally active prodrug of Itaconic acid (HY-Y0520) that efficiently delivers the active ingredient Itaconic acid to skin tissue following oral administration. Itaconic acid prodrug-1 possesses immunomodulatory properties, significantly inhibiting Poly(I:C)/IFNγ-induced inflammatory cytokines in human epidermal keratinocytes. Itaconic acid prodrug-1 can be utilized for the research of alopecia areata and other inflammatory skin diseases .
    Itaconic acid prodrug-1
  • HY-182418
    UR-11353

    		Platelet-activating Factor Receptor (PAFR) Cardiovascular Disease
    UR-11353 is a selective platelet activating factor (PAF) antagonist with long-lasting activity. UR-11353 inhibits PAF-induced platelet aggregation in rabbit platelet-rich plasma. UR-11353 inhibits PAF-induced hypotension in normotensive rats. UR-11353 protects against PAF-induced mortality in mice .
    UR-11353
  • HY-B0426AS2
    Olopatadine-d6 hydrochloride

    ALO4943A-d6 hydrochloride; KW4679-d6 hydrochloride

    		 Isotope-Labeled Compounds Histamine Receptor CXCR Inflammation/Immunology
    Olopatadine-d6 (ALO4943A-d6; KW4679-d6) hydrochloride is deuterium-labeled Olopatadine (hydrochloride) (HY-B0426A). Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 + and CD8 + T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .
    Olopatadine-d6 hydrochloride
  • HY-11024
    ADP receptor-IN-1

    		P2Y Receptor Cardiovascular Disease
    ADP receptor-IN-1 (compound 21) is a platelet ADP receptor inhibitor. ADP receptor-IN-1 shows both IC50 values <10 μM at a platelet ADP receptor binding assay and aggregation using a platelet-rich plasma assay .
    ADP receptor-IN-1
  • HY-10312
    UR-12947

    		Integrin Cardiovascular Disease
    UR-12947 is a platelet glycoprotein (GP) IIb-IIIa antagonist. UR-12947 exhibits potent inhibitory activity against platelet aggregation in human platelet-rich plasma, with an IC50 value of 3.5 nM. UR-12947 can be used in the research of arterial thrombotic diseases .
    UR-12947
  • HY-175986
    IP receptor agonist 1

    		Prostaglandin Receptor Inflammation/Immunology
    IP receptor agonist 1 (compound 6c-14S) is an orally active I prostanoid receptor agonist, with an IC50 of 0.15 μM for inhibiting platelet aggregation induced by ADP (HY-W010918,300 μM) in rabbit platelet-rich plasma. IP receptor agonist 1 can be used for study of Pulmonary arterial hypertension .
    IP receptor agonist 1
  • HY-178913
    Tyk2-IN-23

    		JAK STAT Inflammation/Immunology
    Tyk2-IN-23 is a potent, orally active, selective TYK2 inhibitor (IC50 = 18 nM), exhibiting more than > 70-fold selectivity over JAK1/2/3 isoforms. Tyk2-IN-23 potently inhibits p-STAT3 in TYK2-dependent signaling activated by IFN-α and IL-10. Tyk2-IN-23 potently inhibits IFN-α-induced STAT1 phosphorylation in H9 cells. Tyk2-IN-23 can be used for the study of alopecia areata and allergic Rhinitis .
    Tyk2-IN-23
  • HY-P992122
    Olevaprubart

    		TNF Receptor Inflammation/Immunology
    Olevaprubart is a humanized IgG1-κ monoclonal antibody targeting TNFSF4, which can be used for the research of autoimmune diseases such as atopic dermatitis and alopecia areata .
    Olevaprubart
  • HY-N17941
    19-Anhydro-4-epirotungenic acid

    		Others Cardiovascular Disease
    19-Anhydro-4-epirotungenic acid is a triterpenoid compound that can be isolated from the bark of Ilex rotunda Thunb. 19-Anhydro-4-epirotungenic acid shows no activity against ADP-induced platelet aggregation .
    19-Anhydro-4-epirotungenic acid
  • HY-149310A
    Dim16 hydrochloride

    		PCSK9 HMG-CoA Reductase (HMGCR) Metabolic Disease
    Dim16 hydrochloride is a dual PCSK9 inhibitor and HMG-CoAR inhibitor, with an IC50 of 0.8 nM against human PCSK9 and an IC50 of 146.8 μM against HMG-CoAR. Dim16 hydrochloride disrupts the PCSK9-LDLR protein-protein interaction, inhibits the catalytic activity of HMG-CoAR, enhances cellular uptake of extracellular LDL, and suppresses PCSK9-induced platelet aggregation. Dim16 hydrochloride can be used in research related to hypercholesterolemia .
    Dim16 hydrochloride
  • HY-100754R
    Ritlecitinib (Standard)

    PF-06651600 (Standard)

    		 JAK Reference Standards Interleukin Related STAT Inflammation/Immunology
    Ritlecitinib (Standard) is the analytical standard of Ritlecitinib (HY-100754). This product is intended for research and analytical applications. Ritlecitinib (PF-06651600) is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC50=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC50 >10 μ M). Ritlecitinib rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE) .
    Ritlecitinib (Standard)
  • HY-100754CR
    Ritlecitinib tosylate (Standard)

    PF-06651600 tosylate (Standard)

    		 JAK Reference Standards Interleukin Related STAT Inflammation/Immunology
    Ritlecitinib (tosylate) (Standard) is the analytical standard of Ritlecitinib (tosylate) (HY-100754C). This product is intended for research and analytical applications. Ritlecitinib (PF-06651600) tosylate is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC50=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC50 >10 μ M). Ritlecitinib tosylate rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib tosylate can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE) .
    Ritlecitinib tosylate (Standard)

온라인 문의

Your information is safe with us. * Required Fields.

호칭

  

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

  

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: